Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 6/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1197420 | 0.84 | IDO1 (0.35) | IDO1KITKDRFLT3GSK3B | |
| SCHEMBL16571754 | 0.77 | — | — | |
| SCHEMBL15091080 | 0.76 | CHRNB2 (0.36) | — | |
| SCHEMBL1230717 | 0.72 | MLYCD (0.35) | — | |
| SCHEMBL733028 | 0.71 | ESR1 (0.40) | — | |
| SCHEMBL52685 | 0.70 | CA12 (0.48) | IDO1KITKDRFLT3GSK3B | |
| SCHEMBL29518984 | 0.70 | CA12 (0.48) | IDO1KITKDRFLT3GSK3B | |
| SCHEMBL1461411 | 0.66 | KDM4E (0.33) | — | |
| SCHEMBL2565476 | 0.65 | IDO1 (0.37) | IDO1GSK3B | |
| SCHEMBL30536133 | 0.64 | ESR1 (0.40) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230064443-A1 | 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide Derivatives Useful As a Factor XIa Inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-02 | — | — | US | claimed |
| EP-1841504-B1 | SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-11-19 | — | — | EP | claimed |
| US-8604056-B2 | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-12-10 | — | — | US | claimed |
| US-8466295-B2 | Thiophene derivatives as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-06-18 | — | — | US | claimed |
| US-8410155-B2 | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-02 | — | — | US | claimed |
| US-20120270853-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-10-25 | — | — | US | claimed |
| US-8252830-B2 | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-28 | — | — | US | claimed |
| US-8163749-B2 | Six-membered heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-24 | — | — | US | claimed |
| EP-1981854-B1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-06-01 | — | — | EP | claimed |
| US-20110028446-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-02-03 | — | — | US | claimed |
| US-20060069270-A1 | Process for the preparation of 1,3,5-trisubstituted pyrazoles via [3+2] cycloaddition | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-30 | — | — | US | claimed |
| US-20050245566-A1 | Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones | ZHOU JIACHENG | 2005-11-03 | — | — | US | claimed |
| US-6960595-B2 | 5-6 to 5-7 Heterobicycles as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-01 | — | — | US | claimed |
| US-6919451-B2 | Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-19 | — | — | US | claimed |
| US-20030181466-A1 | Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-25 | — | — | US | claimed |
| US-6465656-B2 | ACYLATING/ACETYLATING ARYLHYDRAZINE, REACTING HYDROZONOYL HALIDE/SULFATE WITH AMINE BASE TO FORM 1-(3-CYANO)PHENYL-2-(TRIFLUOROACETYL)HYDRAZINE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-10-15 | — | — | US | claimed |
| EP-1222172-A1 | SYNTHESIS OF 1,3,5-TRISUBSTITUTED PYRAZOLES AND INTERMEDIATES THEREFORE | Bristol-Myers Squibb Pharma Company (US) | 2002-07-17 | — | — | EP | claimed |
| US-20020055641-A1 | Synthesis of 1,3,5-trisubstituted pyrazoles | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-09 | — | — | US | claimed |
| US-6329527-B1 | ACYLATING SUBSTITUTEDARYL HYDRAZINE, FORMING DIPOLAR COMPOUND, CONTACTING DIPOLAROPHILE AND SUBJECTING TO OXIDATION, REMOVING PROTECTING GROUP | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2001-12-11 | — | — | US | claimed |
| WO-2001029006-A1 | SYNTHESIS OF 1,3,5-TRISUBSTITUTED PYRAZOLES AND INTERMEDIATES THEREFORE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-04-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270853-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | TFPI, F11, F12 | IDO1 865/4885KIT 588/4885KDR 896/4885 |
| US-20020055641-A1 | Synthesis of 1,3,5-trisubstituted pyrazoles | TFPI, SERPINC1, F11 | IDO1 1202/4885KIT 2920/4885KDR 3036/4885 |
| US-20030181466-A1 | Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones | TFPI, TFPI2, F2 | IDO1 703/4885KIT 971/4885KDR 1538/4885 |
| US-20230064443-A1 | 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide Derivatives Useful As a Factor XIa Inhibitors | F11, F12, F13A1 | IDO1 364/4885KIT 531/4885KDR 1883/4885 |
| US-20050245566-A1 | Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones | F2, TFPI, TFPI2 | IDO1 722/4885KIT 1885/4885KDR 1334/4885 |
| US-20060069270-A1 | Process for the preparation of 1,3,5-trisubstituted pyrazoles via [3+2] cycloaddition | TFPI, F2, F11 | IDO1 871/4885KIT 1275/4885KDR 2682/4885 |
| US-20110028446-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | TFPI, F11, F12 | IDO1 865/4885KIT 588/4885KDR 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.